A5035886842- Pharmacological Effects of Natural Compounds
- Enzyme Structure and Function
- Aortic Disease and Treatment Approaches
- Aortic aneurysm repair treatments
- Vascular Procedures and Complications
- Glycosylation and Glycoproteins Research
- Silymarin and Mushroom Poisoning
- Flavonoids in Medical Research
- Cerebrovascular and Carotid Artery Diseases
- Central Venous Catheters and Hemodialysis
- Coronary Interventions and Diagnostics
- Trauma Management and Diagnosis
- Trauma and Emergency Care Studies
- Infectious Aortic and Vascular Conditions
- Vascular anomalies and interventions
- Monoclonal and Polyclonal Antibodies Research
- Cardiac and Coronary Surgery Techniques
- Cancer Diagnosis and Treatment
- Peripheral Artery Disease Management
- Breast Cancer Treatment Studies
- Cancer Mechanisms and Therapy
- Peptidase Inhibition and Analysis
- Breast Implant and Reconstruction
- HER2/EGFR in Cancer Research
Heidelberg Pharma (Germany)
2024-2025
University of Toronto
2019
Princess Margaret Cancer Centre
2019
University Health Network
2019
The University of Texas Health Science Center at San Antonio
2019
Arizona Heart Hospital
2000-2007
Arizona Heart Institute
1999-2002
Purpose:To evaluate the effectiveness of laser-assisted angioplasty for patients with critical limb ischemia (CLI) who were poor candidates surgical revascularization. Methods:A prospective registry at 14 sites in US and Germany enrolled 145 155 critically ischemic limbs; bypass surgery owing to inadequate target vessel or saphenous vein, prohibitive cardiac disease, significant comorbidities (ASA class 4). Additional comorbid risk factors included diabetes 66%, hypertension 83%, previous...
<p>Dose of hRS7 ATAC 1 and 2 with indicated dose α-amanitin used in BxPC-3 Capan-1 dose-response efficacy studies.</p>
<p>MS spectra of DAR determination. Western blotting TROP2 expression on PDAC cell lines. Internalization antibody in In vitro cytotoxicity ADCs MTD and efficacy studies. Spiderplot animals treated with ADCs.</p>
<p>Internalization of hRS7-LALA-DC antibody in PDAC cell lines. Flow cytometry gating was performed according to the PANC-1 cells that do not express TROP2.</p>
<p><i>In </i><i>vivo</i> antitumor efficacy of individual animals treated with Trodelvy compared to hRS7 ATAC 1 in TNBC xenograft mouse model. Female NMRI nude mice bearing HCC70 subcutaneous tumors were either PBS or the indicated doses (cleavable linker) Trodelvy. Efficacy was monitored for 76 days and evaluated by average tumor volume ±SEM, n = 10.</p>
<p>Western blotting of TROP2 expression on PANC-1, BxPC-3, Capan-1 and Capan-2 cells. hRS7-LALA-DC was used as primary antibody rabbit anti-human-IgG-HRP (Abcam) secondary antibody. Chemiluminescence signal detected by WB imager (Azure C400 imaging). The different apparent size TROP-2 in BxPC3 Capan 2 cells is most likely due to differential glycosylation [44] and/or from proteolytic cleavage [45]. In not detected, proteolytical resulting an isoform that cannot be the hRS7 [45], [46].</p>
<p>Deconvoluted MS spectra for hRS7 ATAC 1 (A) and (B) conjugates. The drug-to-antibody (DAR) ratio was measured using intact LC-MS analysis.</p>
<p>a. In vitro cytotoxicity of hRS7 ATAC 1 in tumor cells with medium (A; NCI-N87 cells) and low TROP-2 expression (B; MCF-7 b. PDAC upon transient acidosis or acid adaptation. BxPC-3 (TROP2+++) Capan-1 (TROP2++) were incubated at normal pH 6.6 for 24 hours, 7 days month then treated 96 hours 1. c. Trodelvy TNBC d. <i>In vitro</i> compared to cells.</p>
<p>MTD of hRS7 ATAC 1 and 2. The tolerability was assessed in 7-week-old tumor free female NMRI nude mice by single dose intravenous administration ATACs. At a 10 mg/kg 1, one three animals found dead within 48 h after treatment thus 8 considered to be MTD. ATAC2 tested up maximum 80 – no higher doses were tested. Therefore, the MTD ≥ mg/kg.</p>
<div>Abstract<p>Trophoblast cell surface antigen 2 (TROP2) exhibits aberrant expression in pancreatic cancer, correlating with metastasis, advanced tumor stage, and poor prognosis patients ductal adenocarcinoma. TROP2 has been recognized as a promising therapeutic target for antibody–drug conjugates (ADC), evidenced by the approval of anti-TROP2 ADC Trodelvy treatment triple-negative breast cancer (TNBC). In this study, we report generation novel second-generation amanitin-based...
Abstract Background: About half of the currently FDA-approved antibody drug conjugates (ADCs) are based on microtubule inhibitors, making them effective only against actively dividing cells. Non-dividing tumor stem cells in contrast cannot be eradicated and may cause resistance relapse. Hence, there is a high demand for novel payloads with unique modes action to overcome current limitations. Inhibition NAMPT, rate-limiting enzyme salvage biosynthetic pathway NAD+ starting from nicotinamide,...
PURPOSE To report the immediate endovascular treatment of a thoracic aortic tear secondary to blunt trauma. METHODS AND RESULTS A 39-year-old man was injured in motor vehicle collision. In addition significant trauma head, chest, and abdomen, there were signs deceleration injury aorta. After urgent celiotomy repair lacerated spleen, transection treated intraluminally using an endograft made Gianturco Z-stents covered with polytetrafluoroethylene. The patient recovered from his injuries,...
Purpose: To report the immediate endovascular treatment of a thoracic aortic tear secondary to blunt trauma. Methods and Results: A 39-year-old man was injured in motor vehicle collision. In addition significant trauma head, chest, abdomen, there were signs deceleration injury aorta. After urgent celiotomy repair lacerated spleen, transection treated intraluminally using an endograft made Gianturco Z-stents covered with polytetrafluoroethylene. The patient recovered from his injuries, shows...
Abstract Trophoblast cell surface antigen 2 (TROP2) exhibits aberrant expression in pancreatic cancer, correlating with metastasis, advanced tumor stage and poor prognosis of ductal adenocarcinoma (PDAC) patients. TROP2 has been recognized as a promising therapeutic target for antibody drug conjugates (ADCs), evidenced by the approval anti-TROP2 ADC Trodelvy® treatment triple negative breast cancer. In this study we report generation novel second-generation amanitin based ADCs (ATAC®s)...
Abstract Objective. Breast-conserving therapy with external beam radiotherapy (EBRT) is currently the standard of care for women early breast cancer. Our aim was to determine if early-stage cancers treated lumpectomy and primary intraoperative (IORT) have comparable local recurrence rates. This first study examining Canadian experience IORT. Methods. Patients who underwent breast-conserving pre-pathology IORT between 2007- 2017 were retrospectively identified. The outcome measure ipsilateral...